Skip to Main Content

Author Details

David I Stuart
University of Oxford
1976
462
102
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36619367Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.iScience2023
37515111Structure of Bovine CD46 Ectodomain.Viruses2023
37766989ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.iScience2023
36952226Investigation of the milling characteristics of different focused-ion-beam sources assessed by three-dimensional electron diffraction from crystal lamellae.IUCrJ2023
37286554Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.Nat Commun2023
37285620Broadly neutralizing antibodies against COVID-19.Curr Opin Virol2023
37343087Accelerating drug target inhibitor discovery with a deep generative foundation model.Sci Adv2023
37230988Cryogenic electron ptychographic single particle analysis with wide bandwidth information transfer.Nat Commun2023
36996819Characterization of the rotavirus assembly pathway in situ using cryoelectron tomography.Cell Host Microbe2023
36995936Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses.Cell Rep2023
34987630Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.Theranostics2022
35575895Purification of African Swine Fever Virus.Methods Mol Biol2022
36443292Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.Cell Discov2022
36434067A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.Commun Biol2022
36564504Publisher Correction: A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.Commun Biol2022
36560629Switching of Receptor Binding Poses between Closely Related Enteroviruses.Viruses2022
35969644Nonlytic cellular release of hepatitis A virus requires dual capsid recruitment of the ESCRT-associated Bro1 domain proteins HD-PTP and ALIX.PLoS Pathog2022
36298714Production and Characterisation of Stabilised PV-3 Virus-like Particles Using <i>Pichia pastoris</i>.Viruses2022
36319620Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum.Cell Discov2022
34921776The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.Cell Host Microbe2022
34942101Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.Lancet2022
34873286Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective.Nat Rev Cardiol2022
35081335SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.Cell2022
33420068Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines.NPJ Vaccines2021
33743891Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.Cell2021
33852911Antibody evasion by the P.1 strain of SARS-CoV-2.Cell2021
33602152Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections.BMC Infect Dis2021
33483491A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.Nat Commun2021
33758835Site-specific steric control of SARS-CoV-2 spike glycosylation.bioRxiv2021
33536566Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.Nat Struct Mol Biol2021
33756110The antigenic anatomy of SARS-CoV-2 receptor binding domain.Cell2021
33730597Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.Cell2021
34981049Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.bioRxiv2021
34851350Bacteriophage PRD1 as a nanoscaffold for drug loading.Nanoscale2021
34866631iNEXT-Discovery and Instruct-ERIC: Integrating High-End Services for Translational Research in Structural Biology.J Vis Exp2021
34584208Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.Sci Rep2021
34213308Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation.Biochemistry2021
34242578Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.Cell2021
34168183Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.Sci Rep2021
34111577Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.Clin Microbiol Infect2021
33369366Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.N Engl J Med2021
33248689Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics.Biochem Biophys Res Commun2021
32487987Low-dose phase retrieval of biological specimens using cryo-electron ptychography.Nat Commun2020
34277893CryoSIM: super-resolution 3D structured illumination cryogenic fluorescence microscopy for correlated ultrastructural imaging.Optica2020
31909201Glutathione facilitates enterovirus assembly by binding at a druggable pocket.Commun Biol2020
31911601Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10.Nat Commun2020
33067459Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71.Nat Commun2020
33094717SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020.Euro Surveill2020
32661423Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.Nat Struct Mol Biol2020
32577665Broad and strong memory CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients.bioRxiv2020
  • 1 - 50 of 462

Recommended Authors

Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 2014
Number of shared co-authors 1
Institute for Quantitative Biomedicine, the State University of New Jersey
Career Start Year 2012
Number of shared co-authors 6
The State University of New Jersey
Career Start Year 2009
Number of shared co-authors 6
University of New South Wales
Career Start Year 2007
Number of shared co-authors 4
University of California san francisco
Career Start Year 2005
Number of shared co-authors 2
Stanford University
Career Start Year 2003
Number of shared co-authors 13
Washington University School of Medicine at St. Louis
Career Start Year 2000
Number of shared co-authors 2
Purdue University. Electronic address: .
Career Start Year 2000
Number of shared co-authors 9
Incyte Corporation
Career Start Year 2000
Number of shared co-authors 3
Harvard Medical School
Career Start Year 2000
Number of shared co-authors 3
Poornaprajna Institute of Scientific Research (PPISR)
Career Start Year 1998
Number of shared co-authors 9
McGovern Medical School at the University of Texas Health Science Center
Career Start Year 1998
Number of shared co-authors 11
European Bioinformatics Institute (EMBL-EBI)
Career Start Year 1997
Number of shared co-authors 2
Imperial College London
Career Start Year 1993
Number of shared co-authors 12
Bridge Institute, University of Southern California
Career Start Year 1991
Number of shared co-authors 4
Institute for Protein Research, Osaka University
Career Start Year 1990
Number of shared co-authors 14
European Bioinformatics Institute (EMBL-EBI)
Career Start Year 1990
Number of shared co-authors 22
Heidelberg University
Career Start Year 1989
Number of shared co-authors 0
University of Virginia
Career Start Year 1989
Number of shared co-authors 26
Weizmann Institute of Science
Career Start Year 1988
Number of shared co-authors 7
University of California
Career Start Year 1986
Number of shared co-authors 1
Gladstone Institute of Virology, Gladstone Institutes San Francisco CA USA .
Career Start Year 1985
Number of shared co-authors 5
Cambridge Institute for Medical Research, University of Cambridge
Career Start Year 1982
Number of shared co-authors 16
Institute of Structural and Molecular Biology, University of London
Career Start Year 1976
Number of shared co-authors 3
University of Missouri
Career Start Year 1971
Number of shared co-authors 3
Heartand Lung Research Institute, University of Cambridge
Career Start Year 1971
Number of shared co-authors 9
Columbia University
Career Start Year 1968
Number of shared co-authors 15
University of California San Francisco
Career Start Year 1965
Number of shared co-authors 5
university of california los angeles
Career Start Year 1963
Number of shared co-authors 10
Purdue University
Career Start Year 1960
Number of shared co-authors 18

Collaborators

University of Oxford
Co-authored papers 49
Nankai University
Co-authored papers 25
University of Dundee
Co-authored papers 13
Institute of Biotechnology, University of Helsinki
Co-authored papers 11
Harwell Science & Innovation Campus
Co-authored papers 8
Diamond Light Source Ltd, Harwell Science & Innovation Campus
Co-authored papers 7
Stanford University
Co-authored papers 7
University of Oxford
Co-authored papers 6
Co-authored papers 6
Oxford University.
Co-authored papers 6
Weizmann Institute of Science
Co-authored papers 5
Co-authored papers 5
Co-authored papers 5
National Institutes of Health
Co-authored papers 4
Laboratorio de Virologia do Instituto Leonidas e Maria Deane
Co-authored papers 4
The State University of New Jersey
Co-authored papers 3
Roslin Institute, University of Edinburgh
Co-authored papers 3
Co-authored papers 3
Aix Marseille University and CNRS
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Co-authored papers 2
The Scripps Research Institute, USA The Skaggs Institute for Chemical Biology
Co-authored papers 2
Co-authored papers 2
The University of Edinburgh
Co-authored papers 2
University of Oxford
Co-authored papers 2
University of Leeds
Co-authored papers 2
Washington University School of Medicine
Co-authored papers 2
Leiden University Medical Center
Co-authored papers 2
Leibniz Institute of Virology
Co-authored papers 2